Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04YAdjuvanted vaccine in japanese women

International Journal of Gynecological Cancer

Volumn 19, Issue 5, 2009, Pages 905-911

  Konno, Ryo ^a   Dobbelaere, Kurt O ^b   Godeaux, Olivier O ^b   Tamura, Shinobu ^c   Yoshikawa, Hiroyuki ^d  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c Development and Medical Affairs Division   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cervical cancer; HPV infection; HPV 16 18 AS04 adjuvanted vaccine; Human papillomavirus; Immunogenicity

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY;

ABORTION; ACUTE HEPATITIS; ADULT; APPENDICITIS; ARTHRALGIA; ARTICLE; AVULSION FRACTURE; BLOOD SAMPLING; BRAIN CONTUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; JAPANESE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; PREVALENCE; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SKULL FRACTURE; SPONTANEOUS ABORTION; TONSILLITIS; URTICARIA; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; BLOOD; COHORT ANALYSIS; GENETICS; IMMUNOLOGY; JAPAN; POLYMERASE CHAIN REACTION; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; COHORT STUDIES; DNA, VIRAL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; JAPAN; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 69449084451     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a23c0e     Document Type: Article

References (25)

1. Castellsagué X, de Sanjose S, Aguado T, et al. HPV and Cervical Cancer in the World: 2007 Report. Vaccine. 2007;25S:C1-C26.
2. Ministry of Health, Labour & Walfare. Vital Statistics of Japan. Available at: http://ganjoho.ncc.go.jp/professional/statistics/statistics.html. Accessed May 26, 2008.
3. Marugame T, Matsuda T, Kamo K, et al. Cancer incidence and incidence rates in Japan in 2001 based on the data from 10 population-based cancer registries. Jpn J Clin Oncol. 2007;37:884-891. (Pubitemid 350259009)
4. Konno R, Shin HR, Kim YT, et al. Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine. 2008;26512:M30-M42.
5. Wright TC, Bosch FX, Franco EL, et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine. 2006;24S3: S3251-S3261.
6. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007;98:1505-1511.
7. Miura S, Matsumoto K, Oki A, et al. Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer. 2006; 119:2713-2715.
8. Nakagawa S, Yoshikawa H, Onda T, et al. Type of human papillomavirus is related to clinical features of cervical carcinoma. Cancer. 1996;78: 1935-1941. (Pubitemid 26360577)
9. Smith JS. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-632.
10. Inoue M, Sakaguchi J, Sasagawa T, et al. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer. 2006;16: 1007-1013.
11. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. J Am Med Assoc. 2007;297: 813-819.
12. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004;91:942-953.
13. Beby-Defaux A, Bourgoin A, Ragot S, et al. Human papillomavirus infection of the cervix uteri in women attending a health examination center of the French social security. J Med. Virol. 2004;73:262-268.
14. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000;9:945-951.
15. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24:5937-5949.
16. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.
17. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757Y176517. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
18. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-2170.
19. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007; 40:564-571.
20. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarixi]. Drugs. 2008;68:359-372.
21. Harper DM, Gall S, Naud P, et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarixi (GSK's HPV 16/18 AS04 candidate vaccine). Presented at: 39th Annual Meeting of the Society of Gynecologic Oncologists; March 10, 2008; Florida. Gynecol Oncol. 2008;109:158-159; Abstract 1.
22. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine, recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep. 2007;56:1-24.
23. Aimmugeni [package insert] [in Japanese]. Kumamoto, Japan: Chem-Sero-Therapeutic Research Institute; 2006.
24. Saijo Y, Sato F, Yamada H, et al. Ah receptor, CYP1A2, CYP1A2 and CYP1B1 gene polymorphism are not involved in the risk of recurrent pregnancy loss. Mol Hum Reprod. 2004;10:729-733. (Pubitemid 39341595)
25. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04 adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5:332-340.